Babul N, Pasko M
Beecham Clinical Pharmacology, Canada.
Drug Intell Clin Pharm. 1988 Mar;22(3):218-26. doi: 10.1177/106002808802200309.
The chemistry, microbiology, pharmacokinetics, clinical efficacy, and adverse effect profile of teicoplanin are reviewed and, where appropriate, compared with vancomycin. Teicoplanin is a glycopeptide antibiotic with potent bactericidal activity against a wide variety of aerobic and anaerobic gram-positive bacteria. In contrast to the structurally related vancomycin, teicoplanin has a prolonged elimination half-life of approximately 60 hours and it may be safely administered by the intramuscular route. Adverse effects of teicoplanin include ototoxicity, nephrotoxicity, skin rash, eosinophilia, neutropenia, and transient elevation of serum aminotransferases. Teicoplanin may be beneficial as an alternative to vancomycin for patients with poor vascular access and in those requiring long-term outpatient therapy. The role of teicoplanin in the treatment and prophylaxis of gram-positive infections will ultimately depend on its unfolding safety and efficacy profile.
对替考拉宁的化学、微生物学、药代动力学、临床疗效及不良反应进行综述，并在适当之处与万古霉素作比较。替考拉宁是一种糖肽类抗生素，对多种需氧和厌氧革兰氏阳性菌具有强大的杀菌活性。与结构相关的万古霉素不同，替考拉宁的消除半衰期延长，约为60小时，且可通过肌肉注射途径安全给药。替考拉宁的不良反应包括耳毒性、肾毒性、皮疹、嗜酸性粒细胞增多、中性粒细胞减少及血清转氨酶短暂升高。对于血管通路不佳的患者以及需要长期门诊治疗的患者，替考拉宁作为万古霉素的替代药物可能有益。替考拉宁在革兰氏阳性菌感染治疗和预防中的作用最终将取决于其不断展现出的安全性和疗效。
